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Abstract 48 
Artemisinin induced dormancy is a proposed mechanism for failures of mono-therapy 49 
and is linked with artemisinin resistance in Plasmodium falciparum.  The biological 50 
characterization and dynamics of dormant parasites are not well understood.  Here we 51 
report that following dihydroartemisinin (DHA) treatment in vitro, a small subset of 52 
morphologically dormant parasites was stained with rhodamine 123 (RH), a 53 
mitochondrial membrane potential (MMP) marker, and persisted to recovery.  FACS 54 
sorted RH-positive parasites resumed growth at 10,000/well while RH-negative 55 
parasites failed to recover at 5 million/well. Furthermore, transcriptional activity for 56 
mitochondrial enzymes was only detected in RH-positive dormant parasites. 57 
Importantly, after treating dormant parasites with different concentrations of 58 
atovaquone, a mitochondrial inhibitor, the recovery of dormant parasites was delayed 59 
or stopped. This demonstrates that mitochondrial activity is critical for survival and 60 
regrowth of dormant parasites and that RH staining provides a means of identifying 61 
these parasites. These findings provide novel paths for studying and eradicating this 62 
dormant stage.                            63 
64 
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Introduction   65 
 66 
Artemisinin-based combination therapies are the frontline treatment for 67 
uncomplicated P falciparum malaria and their use has contributed to the worldwide 68 
reduction of malaria incidence rates [1, 2].  Prior to recent reports of emerging 69 
resistance to artemisinins [3-6] evidence showed up to 50% of patients suffered 70 
treatment failures after artemisinin monotherapy, despite parasites being sensitive to 71 
artemisinin class compounds [7]. Antimalarial combinations have significantly 72 
reduced the rate of recrudescence. Understanding mechanisms underlying frequent 73 
recrudescence following artemisinin monotherapy and increasing efficacy of 74 
combination therapies will greatly improve future treatments.   75 
 76 
Recently, treatment failure has been attributed to artemisinin sensitive ring stage 77 
parasites entering growth arrest, referred to as dormancy [8, 9], following artemisinin 78 
monotherapy and resuming growth several days later. Artemisinin induced dormancy 79 
has been observed in vitro [9-11], as well as in vivo in a mouse malaria model [12]. 80 
Proposed to be a stress-response that helps parasites survive artemisinin pressure [13], 81 
dormancy is linked to the ability of parasites to recover from artemisinin treatment at 82 
concentrations up to 7000 times the initial IC50 for up to 96 hours [11]. Teuscher et 83 
al., [14] demonstrated that decreases in the number of parasites entering the dormant 84 
phase may be an indicator of the parasite line’s acquiring resistance to artemisinin. 85 
Similar findings were reported in another laboratory generated artemisinin resistant 86 
line [11] and also in artemisinin resistant field isolates, as increasing ring survival 87 
rates [15]. These studies indicate that dormancy is linked with an artemisinin 88 
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resistance phenotype and understanding how parasites initiate and maintain the 89 
dormant state is important to combat artemisinin resistance. 90 
 91 
Although the phenomenon of dormancy is accepted there are conflicting views about 92 
the morphology of dormant parasites. Teuscher et al. [9] and Tucker et al. [10] 93 
described dormant parasites, whilst similar to the collapsed nuclei of pyknotic forms, 94 
retaining some blue cytoplasm and condensed red chromatin. This morphology is 95 
different from typical ring stage parasites. Witkowski et al. [16] reported that after 96 
treatment with 700 nM dihydroartemisinin (DHA) the morphologically normal 97 
looking ring stage parasites underwent cell cycle arrest and maintained ring 98 
morphology for up to 48 hours. Establishing a biomarker will help identify dormant 99 
parasites and assist investigations into the mechanism of dormancy. 100 
 101 
The dormancy phenomenon is not uncommon in microorganisms. S. cerevisiae enters 102 
a dormant phase during periods of unfavourable growth conditions, where cells stop 103 
glycolysis and start metabolising ethanol through the TCA cycle [17]. Recent studies 104 
show that mutant yeast species, deficient in genes encoding proteins used for 105 
oxidative phosphorylation and other mitochondrial functions, fail to survive the 106 
dormant phase [18]. This indicates that mitochondria are vital to the maintenance of 107 
yeast cells when they enter dormant phase. 108 
 109 
The mitochondria of malaria parasites differs from other eukaryotic cells. It is present 110 
in all stages including ring stage and shares a close association with the apicoplast 111 
[19]. The proximity of these organelles has been hypothesised as necessary for 112 
metabolic interaction [19, 20]. The malarial mitochondrion is involved in metabolic 113 
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pathways including pyrimidine biosynthesis, iron-sulfur cluster and heme biogenesis, 114 
the biosynthesis of ubiquinone and tricarboxylic acid metabolism [21]. Chen et al. 115 
[22] recently reported that both the apicoplast and mitochondrion, remain active in 116 
dormant rings, suggesting an important role for these organelles in the survival and 117 
recovery of dormant parasites.  118 
 119 
To confirm dormant parasites maintain some mitochondrial function and if this could 120 
be used as a biomarker, a mitochondrial dye, Rhodamine 123 (RH), was used for 121 
detection, characterization of the morphology and dynamics of dormant parasites. RH 122 
binds to the mitochondrial membrane of cells and is an indicator of MMP, essential 123 
for mitochondrial function and thus cell viability. Mitochondrial activity has been 124 
measured in another apicomplexan, Toxoplasma gondii using RH [23]. RH has been 125 
used to identify live P.falciparum parasites by flow cytometry [24-27] and show that 126 
parasites treated with antimalarial drugs lost RH staining and never resumed growth 127 
[25].  128 
 129 
Here we report that following DHA treatment in vitro, a small subset of 130 
morphologically dormant parasites was stained with RH and only RH-stained 131 
parasites resumed growth. Furthermore, transcriptional activity of mitochondrial 132 
enzymes was only detected in RH+ve dormant parasites. Importantly, after treating 133 
dormant parasites with atovaquone, a mitochondrial inhibitor, we successfully delayed 134 
the recovery of dormant parasites. This demonstrates that mitochondrial activity is 135 
critical for survival and regrowth of dormant parasites. RH staining can be used as a 136 
means of distinguishing dormant from dead parasites in DHA treated cultures. These 137 
findings provide novel methods for studying and eradicating dormant parasites. 138 
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Methods 139 
 140 
Parasite Cultivation 141 
P.falciparum strain W2 (Indochina), was cultivated using standard techniques in 142 
RPMI 1640 HEPES (Sigma Aldrich) culture medium supplemented with 10% human 143 
plasma and at 3% haematocrit [28].  Prior to each experiment, parasites were 144 
synchronized at ring stage using two rounds of 5% D-sorbitol treatment [29]. 145 
Induction and selection of dormant parasites  146 
Synchronised ring stage parasites were treated with 200 ng/ml DHA (Sigma Aldrich) 147 
for 6 hours then washed with culture medium. The treated culture was passed through 148 
a magnetic column (25 MACS CS separation columns; Miltenyi Biotec) on days 1 to 149 
3 as previously described [9]. Parasite samples were collected before and daily after 150 
DHA treatment in investigations detailed below. Where experiments used Day 2 post-151 
treatment parasites approximately 50% of parasites were morphologically dormant 152 
and remaining parasites were dead [22]. Ring stage W2 parasites were treated with 153 
atovaquone (ATQ) (61 µM, for 24 hours) - a known inhibitor of cytochrome b-c1 154 
complex – that results in a loss MMP. 155 
 156 
Investigating dynamics of RH and SYBR Green (SG) stained parasites following 157 
DHA treatment 158 
 159 
Following DHA, or atovaquone treatment, a daily sample (100 µl) was stained with 160 
either RH (Sigma Aldrich) at 10 µg/ml or SG (10,000x concentration, (Sigma 161 
Aldrich) diluted to 20x concentration, as described in [26] [30] for flow cytometry 162 
analysis.  Thin blood smears were Giemsa stained and examined by microscopy.  163 
8 
 
For FACS analysis, parasites were washed three times in 1xPBS and then analysed in 164 
a FACS Canto II (Becton Dickson, San Jose, CA) using the 488nM blue laser to 165 
determine RH or SG stained fraction. Flow cytometry data, collected from 100,000 166 
events, were analysed using FlowJo software (Treestar).  Stained uninfected RBC 167 
(controls) were gated out and referred to as RH-ve or SG-ve fractions and subtracted 168 
from treatment samples. All other fluorescence events were considered RH+ve or 169 
SG+ve events. The experiment was repeated 3 times using different cultures. 170 
 171 
Investigating recovery of RH and SG stained and unstained parasites 172 
On Day 2 post DHA treatment, parasites were stained with RH, resuspended in 173 
1xPBS and sorted using a FACS Aria live cell sorter (Becton Dickson, San Jose, CA). 174 
Both RH+ve and RH-ve fractions were collected. The RH-ve fractions, were 175 
subsequently stained with SG and resorted (RH-ve/SG+ve). Both RH+ve and RH-176 
ve/SG+ve parasites were then plated out in 96-well plates in triplicate, containing 177 
10,000, 1,000, 100 and 10 sorted parasites/well. A culture containing RH-ve/SG+ve 178 
parasites at 5,000,000 parasites/well was also included. Plates were washed in PBS 179 
and returned to culture conditions. Parasites were monitored every 96 hours, by 180 
microscopy and counted with RH and SG, using a FACS Canto II on the high 181 
throughput sampler option (HTS), to detect parasite growth for 25 days or until they 182 
reached 10% parasitemia. The experiment was repeated 3 times. 183 
 184 
Investigating micrographs of dormant parasites 185 
An aliquot of RH+ve and RH-ve/SG+ve parasites sorted on Day 2 post DHA 186 
treatment was Geimsa stained and examined by light microscope. Parasite images 187 
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were captured with a Jenoptik Progress C14 camera system (Jenoptik, Jena, Germany) 188 
operating Image-Pro software. 189 
 190 
Investigating mitochondrial and apicoplast gene transcription  191 
20,000 RH+ve untreated ring stage parasites and 20,000 each of RH+ve, RH-192 
ve/SG+ve DHA treated ring stage parasites (Day 2 post treatment) were used to 193 
measure transcription of mitochondrial enzymes. RNA isolation and cDNA synthesis 194 
were performed as previously described [22]. Transcriptions of three genes encoding 195 
mitochondrial enzymes including cytochrome c oxidase subunit II (coxii), 196 
flavoprotein subunit of succinate dehydrogenase (sdha) and ubiquinnol-cytochrome c 197 
reductase iron-sulfur subunit (uqcr), and two genes encoding apicoplast enzymes, 198 
lipoyl synthase (lipA) and biotin carboxylase subunit of acetyl CoA carboxylase (bc) 199 
were examined by real time quantitative PCR using gene specific primers and results 200 
normalised as described in [22]. Triplicate samples from three sorts (n=3x3=9) were 201 
analysed and the average quantification cycle (Cq value) calculated.  These values 202 
were compared to those of 20,000 untreated RH+ve parasites to provide a relative 203 
proportion for 20,000 DHA treated RH+ve and RH-ve/SG+ve parasites.   204 
Investigating dynamics of RH and SG stained parasites following exposure to 205 
other artemisinin derivatives 206 
Parasites were treated with artelenic acid (ARTA) (200 ng/ml) or artesunate (AS) 207 
(200 ng/ml) for 6 hrs and monitored daily by FACS using both RH and SG staining as 208 
above. 209 
 210 
Investigating effects of a mitochondrial inhibitor on DHA-induced dormancy 211 
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W2 parasites were treated with DHA (200ng/ml) for 6 hours and subsequently, 24 hrs 212 
after initiation of treatment, were exposed to three concentrations of ATQ, 3nM 213 
(IC90), 30 nM (10x IC90) and 300 nM (100x IC90) for 24 hrs. Parasite recovery was 214 
monitored using RH staining analysed by FACS, against parasites treated with DHA 215 
alone.   216 
Results 217 
Dynamics of RH+ve and SG+ve parasites post DHA treatment 218 
Prior to DHA treatment the number of RH and SG stained parasites, were 2.87% ± 219 
0.09 (mean and SD) and 3.06% ± 0.03, respectively.  RH+ve parasites averaged 94% 220 
SG stained parasites, indicating the majority of parasites have MMP.  221 
 222 
After exposure to DHA the number of SG+ve parasites remained unchanged (3.06% ± 223 
0.03) during the first 24 hours, followed by a slight decline to 2.29% ± 0.07 (74.84% 224 
of pre-treatment) 48 hours after treatment (Figure 1a).  SG+ve parasite counts 225 
decreased to 1.03% ± 0.05 (33.66% of pre-treatment) at 72 hours and further dropped 226 
to an average of 0.04% (1.57% of pre-treatment) at Day 4 until Day 12. SG+ve 227 
parasite counts increased after Day 12, reaching 10% at Day 17 ± 0.3 (mean and SD) 228 
(Figure 1a).  229 
 230 
In contrast, RH+ve parasite density decreased rapidly from pre-treatment parasite 231 
density of 2.87% ± 0.09 to 0.10 % ± 0.01 (3.48% of pre-treatment) at 24 hrs then 232 
declined to 0.03 % ± 0.01 (1.22% of pre-treatment) at 48 hours (Figure 1a). The 233 
RH+ve parasite fraction remained at this level between Days 2 and 12 after treatment, 234 
averaging 0.025% which is 0.87% of the total treated parasite population. This 235 
indicates that a very small proportion (<1%) of DHA treated parasites maintained 236 
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MMP from Day 2 through Day 12. The RH+ve parasite count started to increase after 237 
Day 12, reaching 10% parasitemia  at 16.67 ± 0.33 days (n=3 experiments) (Figure 238 
1a). 239 
 240 
As expected, the proportions of RH+ve to SG+ve parasites decreased markedly (from 241 
93.79% to 3.33%) 24 hrs after DHA treatment (Figure 2.).  This ratio maintained an 242 
average of 2.68% between days 1 and 3, and then increased to 52.15% between days 4 243 
and 12.  These data indicate that among the very small proportion of parasites stained 244 
by SG (~1.5% of pre-treatment) approximately 50% maintained MMP from 4 to 12 245 
days after DHA treatment.  The ratio recovered to pre-treatment levels on Day 17, 246 
indicating that the majority of parasites have MMP similar to pre-treatment.  247 
 248 
 249 
Dynamics of RH+ve and SG+ve parasites post atovaquone treatment 250 
Following atovaquone treatment, SG+ve parasite density remained unchanged in the 251 
first 24 hrs and declined to ~50% 72 hrs post treatment (Figure 1b).  In contrast, 252 
RH+ve parasite density decreased rapidly to 0.00 at 72 hrs.  Unlike post DHA 253 
treatment, no persisting RH+ve stained parasites were detected beyond 72 hours post 254 
atovaquone treatment and the culture had not recovered when monitoring ceased at 255 
Day 25.  256 
 257 
Dynamics of RH+ve and SG+ve parasites after exposure to other 258 
artemisinin derivatives  259 
Both ARTA and AS treatments generated similar dynamic patterns to DHA treatment, 260 
with a small persisting proportion of RH+ve parasites recovering to 10% in 19 and 21 261 
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days, respectively. The density of RH+ve parasites after ARTA and AS treatment was 262 
0.12% ± 0.02 from Day 5 until Day 16 and 0.1% ± 0.01 from Day 2 until Day 15, 263 
respectively, when recovery started. (Figure 1c, 1d).  The RH+ve parasites constituted 264 
1.3% and 1.04% of the ARTA and AS parasites, respectively.  265 
 266 
Micrographs of RH+ve parasites 267 
 268 
Figure 3a shows RH+ve parasites, sorted on Day 2 post-DHA treatment, conform 269 
with the morphology identified by Teuscher et al. [9] and Tucker et al. [10], showing 270 
blue cytoplasm and condensed red chromatin. In contrast, the RH-ve/SG+ve parasites 271 
have collapsed nuclei without cytoplasm.  Compared to untreated rings, dormant rings 272 
have both compact nuclei (stained by SG) and mitochondrion (stained by RH) 273 
consistent with the description by Tucker et al. (Figure 3b) [10]. 274 
 275 
 276 
RH+ve parasites are capable of recovery  277 
To demonstrate the viability of parasite populations, FACS sorted RH+ve and RH-278 
ve/SG+ve parasites were serially diluted and cultured until parasitaemia reached 10% 279 
or until Day 25 post treatment. Parasite growth was observed in all wells containing 280 
RH+ve parasites plated at 10,000 parasites/well, but not in any other cultures (Table 281 
1). 25 days post treatment the 10,000/well culture to reached 10% parasitemia. These 282 
results were reproduced in all three experiments.  283 
 284 
13 
 
Transcription of mitochondrial and apicoplast genes in RH sorted 285 
parasites 286 
Transcription levels of six genes from major metabolic pathways involving the 287 
mitochondria and apicoplast and a control house-keeping gene (sars), were 288 
determined in both RH+ve and RH-ve/SG+ve parasites. In RH+ve parasites, post-289 
DHA treatment transcription levels of sars were reduced to very low levels compared 290 
to untreated rings. In contrast, although the transcription levels of the genes involved 291 
in the mitochondrial electron transport chain, coxii, sdha and uqcr were all reduced 292 
compared to untreated rings they were much higher than sars, maintaining above 15% 293 
of untreated rings (Figure 4). The apicoplast gene involved in fatty acid synthesis, bc, 294 
had transcription levels 176.5% of that observed in untreated rings and the gene 295 
involved in the lipoic acid metabolism, lipA, had transcription levels of 61.85% of 296 
untreated rings (Figure 4).  No transcription was detected for any of these six genes in 297 
the same number of RH-ve/SG+ve parasites.  This suggests that the 298 
mitochondria/apicoplast complex was active in RH+ve, post-DHA treated parasites, 299 
but not active in RH-ve/SG+ve parasites. 300 
 301 
Effect of atovaquone on DHA-induced dormant parasites 302 
A number of combination treatments of DHA/ATQ were tested to see if regrowth 303 
could be curtailed (Figure 5). When ATQ was added after DHA at IC90 level, the time 304 
for parasite recovery to 3% parasitemia was 1 day longer than DHA alone.  Parasite 305 
recovery was further delayed by 6 days when ATQ concentration was at 10x IC90 306 
level. There was no parasite recovery at 25 days when the ATQ concentration was 307 
100x IC90. 308 
 309 
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Discussion 310 
 311 
There is growing evidence that parasites enter a state of dormancy after treatment with 312 
artemisinin class drugs and a small proportion resume growth, likely causing the 313 
clinical recrudescence reported in the field [7]. However, apart from demonstrating 314 
parasites recovering following artemisinin treatment [9], direct evidence showing live 315 
dormant parasites and their dynamics has not been presented.  There is also no reliable 316 
method of identifying dormant parasites. Evidence linking dormancy to resistance 317 
[11, 14, 31, 32] means that it is critical to easily identify and understand the 318 
mechanism parasites use to enter and leave dormancy.  319 
 320 
We have recently demonstrated that pyruvate metabolism and fatty acid synthesis 321 
pathways in the apicoplast remain active in dormant parasites. This was supported by 322 
active transcription of genes encoding key enzymes in these pathways and inhibitors 323 
of these pathways delayed recovery of dormant parasites [22].  We have now further 324 
demonstrated that mitochondrial activity is present in dormant parasites and is critical 325 
for the recovery of dormant parasites. Our data suggest that only parasites with MMP 326 
are able to resume growth providing a good biomarker for dormant parasites.  327 
 328 
The first approach examined the MMP of parasites following DHA treatment using 329 
RH staining. RH is an indicator of MMP and only stains live parasites [27].  We 330 
observed that RH stained parasite density declines rapidly from a pre-treatment level 331 
of 3.3% to an average of 0.02%.  This small population, which is 0.87% of the total 332 
treated parasite population, persisted between Day 2 and Day 12 before increasing 333 
rapidly with parasite recovery. This indicates only a small subset (<1%) of parasites 334 
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retain persisting MMP after exposure to DHA. This proportion is comparable to the 335 
recovery rate reported by Teuscher et al. [9]. Interestingly, of this persisting 336 
population, approximately 50% of parasites retained MMP (RH+ve).   In contrast, this 337 
persisting RH+ve population was not observed in parasites treated with high doses of 338 
atovaquone where no parasite regrowth was observed. ATQ is known to inhibit 339 
electron transport in the parasites’ mitochondria causing death [21], thus providing a 340 
good negative (dead) control.  The fact that ATQ treated parasites did not stain with 341 
RH at 72 hrs post treatment indicated no persisting dormant parasites following ATQ 342 
treatment, evidenced by no recovery of parasites from the culture. This suggests that 343 
the RH+ve population were the “seed” for recovery after DHA treatment. A similar 344 
pattern was observed in ARTA and AS treated parasites, suggesting this subset of 345 
parasites with MMP exist following treatment with artemisinin class drugs.  346 
 347 
The second approach was the recovery experiments, where DHA treated parasites 348 
were sorted then cultured to see whether they could regrow. This experiment clearly 349 
showed that parasites retaining MMP (RH+ve) resumed growth at 10,000/well, while 350 
parasites that lost MMP (RH-ve/ SG+ve) failed to recover even at the higher 351 
concentration of 5,000,000/well.  This demonstrates that only RH+ve parasites are 352 
truly dormant parasites, with the ability to regrow. The recovery rate of RH+ve 353 
parasites on Day 2 post DHA treatment was estimated to be at a minimum of 1/10,000 354 
(0.01%) because all of the 10,000/well parasite cultures recovered to 10% 355 
parasitemia. This rate is lower than that reported earlier [9]. In addition, the time taken 356 
for these cultures to reach 10% (25 days) was longer than that required for the 357 
unsorted (16 days, Figure 1a) or for dormant parasites (19 days) from earlier 358 
experiments [32].  This delay in regrowth could be due to deleterious effect of 359 
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staining [33] and the sorting process on the parasites which can take up to 4 hours and 360 
during this time the dormant parasites are in PBS at room temperature.    Furthermore, 361 
the actual sorting through the FACS Aria can cause damage to the sorted cells. There 362 
was evidence, on slides made from the sorted parasites, of damage to the parasitised 363 
red cells, which would affect viability and reduce rates of recovery.  364 
 365 
The third approach was to assess whether a mitochondrial inhibitor could suppress 366 
mitochondrial activity in dormant parasites and prevent their recovery. When ATQ 367 
was added to DHA treated parasites at lower concentrations, it delayed the parasite 368 
recovery by up to 6 days.  At 100x IC90, atovaquone stopped the regrowth of dormant 369 
parasites.  Our previous research showed that treatment with mefloquine after DHA 370 
treatment was able to slow the regrowth of dormant parasites. The exact mechanism 371 
of mefloquine’s action on dormant parasites is not clear. 372 
 373 
The fourth approach was measuring transcription levels of several genes associated 374 
with the mitochondria and apicoplast in RH+ve and RH-ve parasites. Transcripts of 375 
three mitochondrial genes involved in the electron transport and two apicoplast genes 376 
were detected in RH+ve parasites. This was not surprising as there is good evidence 377 
that together these two organelles provide the metabolic activity required for parasite 378 
growth and development during the ring stage [19, 20]. However, this is in sharp 379 
contrast to RH-ve/SG+ve parasites where no transcription of these genes was 380 
detected.  It is likely that mitochondrial activities provide energy to maintain the 381 
viability of dormant parasites and power their recovery.   382 
 383 
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RH-staining also provided an excellent means to determine the morphology of DHA 384 
induced dormant parasites.  Our data show that RH+ve parasites looked like the 385 
“pyknotic” forms described by Teuscher [9] and Tucker [10], not a normal ring stage 386 
morphology. In addition, the parasites showed small compact mitochondria as 387 
opposed to the branched mitochondrial staining patterns of untreated rings reported by 388 
van Dooran et al. [34].  In contrast to RH, although SG staining has been used 389 
effectively to evaluate parasitemia of P.falciparum [35] we found SG cannot 390 
distinguish between live and dead parasites as the number of SG+ve parasites 391 
decreases much slower after DHA treatment, compared to RH+ve, presumably after 392 
DNA decays in dead parasites. These experiments used W2 parasites but the 393 
techniques have worked on several parasite strains. Should further studies be 394 
undertaken into resistance and dormancy other strains and indeed a variety of strains 395 
will need to be used.  396 
 397 
Combined, these approaches demonstrated that a small subset of parasites maintained 398 
MMP and maintained transcription of key enzymes in the mitochondria and apicoplast 399 
following exposure to artemisinin class compounds.  This subset of parasites was 400 
identifiable by RH staining and was responsible for recovery from dormancy.  401 
Inhibiting mitochondrial activity following DHA treatment can kill dormant parasites 402 
preventing recovery. These findings not only help to understand the dormancy 403 
phenomenon that parasites use to escape artemisinin drug pressure, but also provide a 404 
means for identifying and purifying dormant parasites following artemisinin 405 
treatment. This will greatly enhance our ability to undertake more detailed studies of 406 
this parasite stage and may lead to new avenues for better targeting this “Sleeping 407 
Beauty” of P.falciparum to improve artemisinin efficacy. 408 
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 522 
 523 
Figure 1. The density of parasites detected by rhodamine 123 (grey) and sybr green 524 
(black) staining following dihydroartemisinin (a), atovaquone (b),  artelenic acid (c) 525 
and artesunate (d) treatment. All cultures started at 2% parasitemia except the 526 
atovaquone treated culture which started at 1%. These data are the result of three 527 
separate experiments. Mean and SD shown. 528 
529 
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 530 
 531 
Figure 2. The graph shows the proportion of RH+ve parasites relative to SG+ve 532 
parasites after DHA treatment until recovery.  533 
 534 
 535 
536 
25 
 
Table 1. Recovery of RH+ve and RH-ve/SG+ve parasites after DHA treatment. 537 
Parasites were live sorted by FACS Aria. Cultures with 10, 100, 1000 and 10,000 538 
parasites were then grown to 10% or until day 25 post treatment if no parasites were 539 
detected by FACs. 540 
Parasite 
Population 
Parasites 
per well 
Regrowth 
Well 1 Well 2 Well 3 
RH+ve 
10 NO NO NO 
100 NO NO NO 
1000 NO NO NO 
10,000 YES YES YES 
     
RH-ve 
/SG+ve 
10 NO NO NO 
100 NO NO NO 
1000 NO NO NO 
10,000 NO NO NO 
5,000,000 NO NO NO 
 541 
 542 
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 543 
Figure 3a.  Micrographs of parasites live sorted by FACS Aria. 100 000 parasites 544 
were sorted and then giemsa stained and photographed. The chosen cells are 545 
representative of 91 % of all RH+ve cells observed (the rest were uninfected 546 
erythrocytes) and 88% for RH –ve/SG+ve cells sorted (the rest were uninfected 547 
erythrocytes). 548 
 549 
 550 
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Figure 3b. Fluorescent images of  P. falciparum rings before and after treatment with 551 
DHA. Ring stage parasites (after sorbitol treatment) were treated with either and RH 552 
or SG and images taken. For DHA treated parasites images were taken on day 2 post 553 
treatment. 554 
555 
28 
 
 556 
Figure 4. Transcription levels of 6 genes in 20,000 DHA treated, RH+ve parasites 557 
relative to 20,000 untreated RH+ve ring stage parasites. The graph shows 558 
transcription levels of seryl-tRNA synthetase (sars) a control gene and three genes 559 
encoding mitochondrial enzymes cytochrome c oxidase subunit II (coxii), flavoprotein 560 
subunit of succinate dehydrogenase (sdha), ubiquinnol-cytochrome c reductase iron-561 
sulfur subunit (uqcr) and two genes encoding apicoplast enzymes, lipoyl synthase 562 
(lipA) and biotin carboxylase subunit of acetyl CoA carboxylase (bc) Mean and SD 563 
shown. 564 
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 566 
Figure 5. Density of parasites after treatment with DHA (black line) and ATQ (IC 90 567 
[blue], 10X IC90 [green] and 100X IC90 [red]). Mean and SD shown. 568 
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